Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals director B. Lynne Parshall sold 5,000 shares of Ionis common stock on 08/06/2025 under a pre-established Rule 10b5-1 trading plan adopted May 6, 2025. The filings report two sales: 4,600 shares at a weighted-average price of $41.8685 (individual trade prices ranged from $41.50 to $42.36) and 400 shares at a weighted-average price of $42.6275 (individual trade prices ranged from $42.56 to $42.83). Following the reported transactions, the Form 4 shows beneficial ownership figures of 86,744 shares and 86,344 shares respectively. The reporting person is identified as a director and the sales were executed pursuant to the disclosed trading plan.
Filing type: Form 144 notice for Ionis Pharmaceuticals, Inc. (IONS).
Proposed sale: 10,000 shares of Common Stock through Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO) on 08/06/2025, with an aggregate market value of $419,292.00. The filing lists 159,391,229 shares outstanding.
Acquisition details: 42,223 shares were acquired as Restricted Stock Units on 01/15/2017; payment: Cash. The filing shows "Nothing to Report" for securities sold in the past 3 months. The filer identity/CIK and submission contact fields are not provided in the form content.
Ionis Pharmaceuticals (IONS) filed a Form 4 stating that EVP & Chief Clinical Development Officer Eugene Schneider sold 9,549 common shares on 08/04/2025 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted 05/02/2025. The weighted-average sale price was $42.8004, with individual trades executed between $42.315 and $43.45. Gross proceeds are roughly $0.41 million.
Following the disposition, Schneider directly owns 51,507 shares; the sale reduced his direct stake by approximately 15.6 % (from 61,056 shares). No derivative securities were involved. The filing is a routine Section 16 disclosure and does not affect the company’s operations or guidance.
Q2-25 results (ended 30 Jun 25): Ionis generated $452.0 M revenue, +101% YoY, fuelled by a $280 M upfront from Ono (sapablursen), a $30 M milestone from AstraZeneca and $19.3 M of first-time U.S. TRYNGOLZA sales. Royalty streams (mostly SPINRAZA & WAINUA) added $70.0 M.
Operating expenses rose 7% to $312.2 M as SG&A expanded with launches while R&D fell modestly; operating profit reached $139.8 M versus a $66.1 M loss. Net income swung to $123.6 M ($0.70 diluted EPS) from a $66.3 M loss.
H1-25: Revenue climbed 69% to $583.7 M; net loss narrowed to $23.4 M. Operating cash flow was essentially breakeven ( $0.6 M) versus a $269.8 M outflow a year earlier.
Balance sheet: Cash increased to $297.3 M; cash + short-term investments totalled ~$2.29 B. Shareholders’ equity improved to $631.7 M. Current liabilities grew to $897.2 M after the 0% convertible notes ($630.1 M) moved current; total liabilities stand at $2.35 B.
Strategic updates: 1) Ono deal brings up to $940 M future milestones; 2) AstraZeneca advanced opemalirsen into Phase 2b; 3) first independent commercial launch with FDA-approved TRYNGOLZA for FCS. Company maintains single-segment reporting and full valuation allowance on deferred tax assets.